Matrix metalloproteinase (MMP)-2 genetic variants modify the circulating MMP-2 levels in end-stage kidney disease

American Journal of Nephrology

Volumn 35, Issue 3, 2012, Pages 209-215

  Marson, Bernardo P ^a   Lacchini, Riccardo ^b   Belo, Vanessa ^b   Dickel, Samantha ^c   Da Costa, Bartira P ^c   Poli De Figueiredo, Carlos E ^c   Tanus Santos, Jose E ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

End stage kidney disease; Haplotypes; Hemodialysis; Matrix metalloproteinase 2; Polymorphisms; Tissue inhibitor of metalloproteinases 2

Indexed keywords

BIOLOGICAL MARKER; CREATININE; GELATIN; GELATINASE A; HEMOGLOBIN; PHOSPHORUS; POTASSIUM; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTERIAL PRESSURE; ARTICLE; BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEMATOCRIT; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; ZYMOGRAPHY;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; POLYMORPHISM, GENETIC; RENAL DIALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84856496775     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000336108     Document Type: Article

References (30)

1. Page-McCaw A, Ewald AJ, Werb Z: Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007;8: 21-233.
2. Catania JM, Chen G, Parrish AR: Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 2007; 292:F905-F911. (Pubitemid 46393417)
3. Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, Iskandrian AE: The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 2009;53:2129-2140.
4. Kumata C, Mizobuchi M, Ogata H, Koiwa F, Kondo F, Kinugasa E, Akizawa T: Involvement of matrix metalloproteinase-2 in the development of medial layer vascular calcification in uremic rats. Ther Apher Dial 2011;15(suppl 1):18-22.
5. Pai A, Leaf EM, El-Abbadi M, Giachelli CM: Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease. Am J Pathol 2011;178:764-773.
6. Chen NX, O'Neill KD, Chen X, Kiattisunthorn K, Gattone VH, Moe SM: Activation of arterial matrix metalloproteinases leads to vascular calcification in chronic kidney disease. Am J Nephrol 2011;34:211-219.
7. Chung AW, Yang HH, Kim JM, Sigrist MK, Chum E, Gourlay WA, Levin A: Upregulation of matrix metalloproteinase-2 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney disease. Circulation 2009;120:792-801.
8. Pawlak K, Pawlak D, Mysliwiec M: Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients. Atherosclerosis 2007;190: 199-204. (Pubitemid 44908316)
9. Pawlak K, Tankiewicz J, Mysliwiec M, Pawlak D: Systemic levels of MMP2/TIMP2 and cardiovascular risk in CAPD patients. Nephron Clin Pract 2010;;115:C251-C258.
10. Musial K, Zwolinska D: Matrix metalloproteinases and soluble Fas/FasL system as novel regulators of apoptosis in children and young adults on chronic dialysis. Apoptosis 2011;16:653-659.
11. Pawlak K, Mysliwiec M, Pawlak D: Peripheral blood level alterations of MMP-2 and MMP-9 in patients with chronic kidney disease on conservative treatment and on hemodialysis. Clin Biochem 2011;44:838-843.
12. Friese RS, Rao F, Khandrika S, Thomas B, Ziegler MG, Schmid-Schonbein GW, O'Connor DT: Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease. Clin Exp Hypertens 2009;31:521-533.
13. Preston GA, Barrett CV, Alcorta DA, Hogan SL, Dinwiddie L, Jennette JC, Falk RJ: Serum matrix metalloproteinases MMP-2 and MMP-3 levels in dialysis patients vary independently of CRP and IL-6 levels. Nephron 2002;92:817-823. (Pubitemid 36151362)
14. Rysz J, Banach M, Stolarek RA, Mikhailidis DP, Cialkowska-Rysz A, Pokoca L, Piechota M, Baj Z: Serum metalloproteinases mmp-2, mmp-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis. Int Urol Nephrol 2011;43:491-498.
15. Chou FP, Chu SC, Cheng MC, Yang SF, Cheung WN, Chiou HL, Hsieh YS: Effect of hemodialysis on the plasma level of type IV collagenases and their inhibitors. Clin Biochem 2002;35:383-388.
16. Jacob-Ferreira AL, Lacchini R, Gerlach RF, Passos CJ, Barbosa F Jr, Tanus-Santos JE: A common matrix metalloproteinase (MMP)- 2 polymorphism affects plasma MMP-2 levels in subjects environmentally exposed to mercury. Sci Total Environ 2011;409: 242-4246.
17. Singh R, Srivastava P, Srivastava A, Mittal RD: Matrix metalloproteinase (MMP-9 and MMP-2) gene polymorphisms influence allograft survival in renal transplant recipients. Nephrol Dial Transplant 2010;25:3393-3401.
18. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D: Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 2004;64:7622-7628. (Pubitemid 39372109)
19. Price SJ, Greaves DR, Watkins H: Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 2001;276:7549-7558.
20. Manso H, Krug T, Sobral J, Albergaria I, Gaspar G, Ferro JM, Oliveira SA, Vicente AM: Variants of the matrix metalloproteinase-2 but not the matrix metalloproteinase-9 genes significantly influence functional outcome after stroke. BMC Med Genet 2010;11:40.
21. Langers AM, Verspaget HW, Hommes DW, Sier CF: Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer. World J Gastrointest Oncol 2011; 3:79-98.
22. Lacchini R, Jacob-Ferreira AL, Luizon MR, Gasparini S, Ferreira-Sae MC, Schreiber R, Nadruz W Jr, Tanus-Santos JE: Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients. J Hum Hypertens 2011 (E-pub ahead of print).
23. Gerlach RF, Demacq C, Jung K, Tanus-Santos JE: Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 2007;40:119-123. (Pubitemid 46014168)
24. Lacchini R, Metzger IF, Luizon M, Ishizawa M, Tanus-Santos JE: Interethnic differences in the distribution of matrix metalloproteinases genetic polymorphisms are consistent with interethnic differences in disease prevalence. DNA Cell Biol 2010;29:649-655.
25. Chung AW, Yang HH, Sigrist MK, Brin G, Chum E, Gourlay WA, Levin A: Matrix metalloproteinase- 2 and -9 exacerbate arterial stiffening and angiogenesis in diabetes and chronic kidney disease. Cardiovasc Res 2009;84:494-504.
26. Rizzi E, Castro MM, Prado CM, Silva CA, Fazan R Jr, Rossi MA, Tanus-Santos JE, Gerlach RF: Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. J Card Fail 2010;16:599-608.
27. Chancey AL, Brower GL, Peterson JT, Janicki JS: Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 2002;105:1983-1988. (Pubitemid 34437628)
28. Guimaraes DA, Rizzi E, Ceron CS, Oliveira AM, Oliveira DM, Castro MM, Tirapelli CR, Gerlach RF, Tanus-Santos JE: Doxycycline dose-dependently inhibits MMP-2-mediated vascular changes in 2K1C hypertension. Basic Clin Pharmacol Toxicol 2011;108:318-325.
29. Ceron C, Castro M, Rizzi E, Montenegro M, Fontana V, Salgado M, Gerlach R, Tanus- Santos J: Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol 2010;160:77-87.
30. Martinez ML, Rizzi E, Castro MM, Fernandes K, Bendhack LM, Gerlach RF, Tanus- Santos JE: Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats. Eur J Pharmacol 2008;599:110-116.